Solventum Corporation $SOLV Shares Sold by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. cut its holdings in Solventum Corporation (NYSE:SOLV) by 5.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 148,679 shares of the company’s stock after selling 9,169 shares during the quarter. PNC Financial Services Group Inc. owned about 0.09% of Solventum worth $9,709,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of SOLV. Independent Franchise Partners LLP raised its holdings in shares of Solventum by 19.0% in the 4th quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company’s stock worth $1,216,785,000 after purchasing an additional 2,456,451 shares in the last quarter. Norges Bank bought a new stake in Solventum during the fourth quarter worth approximately $147,467,000. Diamond Hill Capital Management Inc. boosted its holdings in Solventum by 152.2% during the fourth quarter. Diamond Hill Capital Management Inc. now owns 2,109,027 shares of the company’s stock worth $167,119,000 after buying an additional 1,272,921 shares in the last quarter. Boston Partners grew its position in Solventum by 26.1% in the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock worth $338,006,000 after buying an additional 959,543 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Solventum by 20.0% in the fourth quarter. Geode Capital Management LLC now owns 4,588,728 shares of the company’s stock valued at $362,375,000 after buying an additional 763,308 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on SOLV. BTIG Research reiterated a “buy” rating and set a $91.00 price objective on shares of Solventum in a research report on Monday, July 13th. Wells Fargo & Company cut their target price on Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research report on Wednesday, May 6th. KeyCorp boosted their target price on Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Piper Sandler reduced their target price on Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Finally, UBS Group lowered Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price target for the company. in a research report on Thursday, May 14th. Six equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $81.91.

Solventum Stock Up 1.0%

Shares of NYSE:SOLV opened at $78.02 on Friday. The firm has a 50 day simple moving average of $77.47 and a 200 day simple moving average of $74.22. Solventum Corporation has a 52 week low of $62.38 and a 52 week high of $88.20. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.75 and a current ratio of 1.07. The company has a market cap of $13.51 billion, a PE ratio of 9.56, a price-to-earnings-growth ratio of 1.20 and a beta of 0.66.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.35 by $0.13. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The firm had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. During the same period in the previous year, the company posted $1.34 EPS. The company’s quarterly revenue was down 3.0% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, research analysts expect that Solventum Corporation will post 6.58 earnings per share for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.